Contraception

Mystery client study investigating the number of appointments required for IUD insertions and whether availability of IUD insertion varied based on prospective patient age, race or parity (study location: Ohio).

Excel database of 1200 participants to the prospective descriptive study of the risk of vasectomy failure by ligation and excision with fascial interposition.

Texas abortion cases by county and race-ethnicity for 2012 and 2015

An optimized time interval between mifepristone and misoprostol administration for management of early pregnancy loss

Raw data, frequency tables

We conducted four cross-sectional microcosting studies in three countries (Burkina Faso, Senegal and Uganda) from December 2015 to January 2017. This data set includes primary data collected from health facilities on the resources used for injectable contraceptive (DMPA-IM and DMPA-SC) service delivery through three different strategies--facility-based administration, community-based administration and self-injection.

A similar study was conducted on women who received DMPA-IM or DMPA-SC injections from facility-based health workers in Burkina Faso. The data can be found in this same Dataverse folder, and the results are described in the linked publication.

A similar study was conducted on women who received DMPA-IM or DMPA-SC injections from community-based health workers in Uganda. The data can be found in this same Dataverse folder, and the results are described in the linked publication.

The purpose of this study was to compare 12-month continuation rates for subcutaneous depot medroxyprogesterone acetate (DMPA-SC) administered via self-injection and DMPA-IM administered by a facility-based health worker in Uganda. Women seeking injectable contraception at participating health facilities were offered the choice of self-injecting DMPA-SC or receiving an injection of DMPA-IM from a health worker. Those opting for self-injection were trained one-on-one. They self-injected under supervision and took home three units, a client instruction guide and a reinjection calendar. Those opting for DMPA-IM received an injection and an appointment card for the next facility visit in 3 months. We interviewed participants at baseline (first injection) and after 3 (second injection), 6 (third injection) and 9 (fourth injection) months, or upon discontinuation. Information from all interviews are included in this dataset, and can be downloaded from the files section. Information on the methods and results from this study can be found in the linked publication.

This dataset contains monitoring data from the pilot introduction of subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) in Nigeria's private and public sectors, from January 1, 2015 through December 31, 2017.